Treatment factors examined that are associated with improved survival in oral cavity cancer

Share this content:

Neck dissection of lymph nodes and receiving treatment at academic or research institutions were both associated with improved survival for patients with stages I and II oral cavity squamous cell cancer (OCSCC), according to a report in JAMA Otolaryngology-Head & Neck Surgery (2015; doi:10.1001/.jamaoto.2015.0719).

Approximately 28,000 cases of OCSCC occurred in the United States in 2014, with an estimated 5,500 deaths predicted. Approximately 60% of patients with OCSCC are initially seen with early stage disease (stage I or II). Prognosis depends on many factors, including patient age, stage at diagnosis, and the primary site of the disease. The average 5-year survival rate is 80%.

Treatment of early OCSCC has not changed substantially in several decades and improvement in outcomes has been slow. The role of neck dissection in early OCSCC remains controversial, according to the study background.

Benjamin L. Judson, MD, of the Yale University School of Medicine, New Haven, Connecticut, and coauthors analyzed the associations between various treatment characteristics and survival in stages I and II OCSCC. The study was a review of cases in the National Cancer Data Base and included 6,830 patients.

Survival at 5 years was 69.7% (4,760 patients), according to the study results. The authors found neck dissection and treatment at academic or research institutions were associated with improved survival, while positive margins, insurance through Medicare or Medicaid, and radiation or chemotherapy were associated with reduced survival.

Patients treated at academic or research cancer centers were more likely to receive neck dissection and were less likely to receive radiation therapy or have positive margins than those patients treated at nonacademic centers.

“Identification of the underlying causes of these differences could reveal valuable targets for improvement of outcomes in early OCSCC,” the study concluded. The study was supported by the William U. Gardner Memorial Research Fund at Yale University School of Medicine.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs